A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Craig Wiesenhutter, MD
Coeur d Alene Arthritis Clinic
Principal Investigator - Daniel Wallace, MD
Wallace Rheumatic Study Center
Principal Investigator - Jerry Molitor, MD, PhD
Benaroya Research Institute at Virginia Mason
Principal Investigator - Joel Kremer, MD
The Center for Rheumatology
Principal Investigator - Justus J. Fiechtner, MD
Justus Fiechtner MD PC
Principal Investigator - Mark C. Genovese, MD
Stanford University Medical Center-Div. of Rheumatology
Principal InvestigatorKOL profile → - Michael H. Schiff, MD
Denver Arthritis Clinic
Principal Investigator - Robert S. Katz, MD
Rheumatology Associates Clinical Research
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Wallace Rheumatic Study Center
Los Angeles, California, United States
- Stanford University Medical Center-Div. of Rheumatology
Palo Alto, California, United States
- Denver Arthritis Clinic
Denver, Colorado, United States
- Coeur D Alene Arthritis Clinic
Coeur d'Alene, Idaho, United States
- Rheumatology Associates Clinical Research
Chicago, Illinois, United States
- Justus J. Fiechtner Md Pc
Lansing, Michigan, United States
- the Center for Rheumatology
Albany, New York, United States
- Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
- Benaroya Research Institute at Virginia Mason
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2005
- Primary completion
- —
- Completion
- 31 Dec 2006
- Last update posted
- 5 Aug 2008
- Registered enrollment
- 40
- Registry id
- NCT00281294
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.